<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US7029659 - aqueous solvent, organic cosolvent, and occlusive agent, especially ... - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_8a2b04e7bf975d5171d8e4c0b6365c7a/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_8a2b04e7bf975d5171d8e4c0b6365c7a__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="aqueous solvent, organic cosolvent, and occlusive agent, especially petrolatum, to form an occlusive layer on the skin for the topical administration of pharmaceuticals"><meta name="DC.contributor" content="Albert Zorko Abram" scheme="inventor"><meta name="DC.contributor" content="Connetics Australia Pty Ltd." scheme="assignee"><meta name="DC.date" content="2004-1-27" scheme="dateSubmitted"><meta name="DC.description" content="A topical mousse composition including an occlusive agent; an aqueous solvent; and an organic cosolvent, wherein the occlusive agent is present in an amount sufficient to form an occlusive layer on the skin."><meta name="DC.date" content="2006-4-18" scheme="issued"><meta name="DC.relation" content="EP:0484530:A1" scheme="references"><meta name="DC.relation" content="GB:2327344" scheme="references"><meta name="DC.relation" content="US:5143717" scheme="references"><meta name="DC.relation" content="US:5733558" scheme="references"><meta name="DC.relation" content="US:5833960" scheme="references"><meta name="DC.relation" content="US:6730288" scheme="references"><meta name="DC.relation" content="WO:1993025189:A1" scheme="references"><meta name="DC.relation" content="WO:1996027376:A1" scheme="references"><meta name="DC.relation" content="WO:1999004751:A2" scheme="references"><meta name="DC.relation" content="WO:2000015193:A1" scheme="references"><meta name="citation_reference" content="Zorko, et al., &quot;Mousses&quot;; Handbook of Cosmetic Science and Technology; pp. 221-232; Marcel Dekker, Inc.; New York (2000)."><meta name="citation_patent_number" content="US:7029659"><meta name="citation_patent_application_number" content="US:10/766,202"><link rel="canonical" href="http://www.google.com/patents/US7029659"/><meta property="og:url" content="http://www.google.com/patents/US7029659"/><meta name="title" content="Patent US7029659 - aqueous solvent, organic cosolvent, and occlusive agent, especially petrolatum, to form an occlusive layer on the skin for the topical administration of pharmaceuticals"/><meta name="description" content="A topical mousse composition including an occlusive agent; an aqueous solvent; and an organic cosolvent, wherein the occlusive agent is present in an amount sufficient to form an occlusive layer on the skin."/><meta property="og:title" content="Patent US7029659 - aqueous solvent, organic cosolvent, and occlusive agent, especially petrolatum, to form an occlusive layer on the skin for the topical administration of pharmaceuticals"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("IabtU8mTEMP0oAS_rYFQ"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407723702.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("NZL"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("IabtU8mTEMP0oAS_rYFQ"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407723702.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("NZL"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us7029659?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US7029659"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=7qByBAABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS7029659&amp;usg=AFQjCNEJlXqG17pu21TaFluhRhmOtp9eoQ" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US7029659.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US7029659.pdf"></a><a class="appbar-application-grant-link" data-label="Application" href="/patents/US20040184992"></a><a class="appbar-application-grant-link" data-selected="true" data-label="Grant" href="/patents/US7029659"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US7029659" style="display:none"><span itemprop="description">A topical mousse composition including an occlusive agent; an aqueous solvent; and an organic cosolvent, wherein the occlusive agent is present in an amount sufficient to form an occlusive layer on the skin....</span><span itemprop="url">http://www.google.com/patents/US7029659?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US7029659 - aqueous solvent, organic cosolvent, and occlusive agent, especially petrolatum, to form an occlusive layer on the skin for the topical administration of pharmaceuticals</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US7029659 - aqueous solvent, organic cosolvent, and occlusive agent, especially petrolatum, to form an occlusive layer on the skin for the topical administration of pharmaceuticals" title="Patent US7029659 - aqueous solvent, organic cosolvent, and occlusive agent, especially petrolatum, to form an occlusive layer on the skin for the topical administration of pharmaceuticals"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US7029659 B2</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 10/766,202</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Apr 18, 2006</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">Jan 27, 2004</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">Sep 11, 1998</td></tr><tr><td class="patent-bibdata-heading">Fee status<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The fee status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status or dates listed."></span></td><td class="single-patent-bibdata">Paid</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/CA2333869A1">CA2333869A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/CA2333869C">CA2333869C</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE69937802D1">DE69937802D1</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE69937802T2">DE69937802T2</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1112062A1">EP1112062A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1112062A4">EP1112062A4</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1112062B1">EP1112062B1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1872776A2">EP1872776A2</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1872776A3">EP1872776A3</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1872776B1">EP1872776B1</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6730288">US6730288</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20040184992">US20040184992</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20060104912">US20060104912</a>, </span><span class="patent-bibdata-value"><a href="/patents/WO2000015193A1">WO2000015193A1</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">10766202, </span><span class="patent-bibdata-value">766202, </span><span class="patent-bibdata-value">US 7029659 B2, </span><span class="patent-bibdata-value">US 7029659B2, </span><span class="patent-bibdata-value">US-B2-7029659, </span><span class="patent-bibdata-value">US7029659 B2, </span><span class="patent-bibdata-value">US7029659B2</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Albert+Zorko+Abram%22">Albert Zorko Abram</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Connetics+Australia+Pty+Ltd.%22">Connetics Australia Pty Ltd.</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US7029659.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US7029659.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US7029659.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (10),</span> <span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (1),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (7),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (35),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (7)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/7029659&usg=AFQjCNEB042HHWb37ZAfnCWPR9DPFyGV5A">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D7029659&usg=AFQjCNE_u35y68h034Y6uiXjhoce-ijOBA">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D7029659B2%26KC%3DB2%26FT%3DD&usg=AFQjCNGcMDEKYfkXUHoB014A66ezzFkrWA">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT129827635" lang="EN" load-source="ifi">aqueous solvent, organic cosolvent, and occlusive agent, especially petrolatum, to form an occlusive layer on the skin for the topical administration of pharmaceuticals</invention-title></span><br><span class="patent-number">US 7029659 B2</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA50962847" lang="EN" load-source="patent-office"> <div num="p-0001" class="abstract">A topical mousse composition including an occlusive agent; an aqueous solvent; and an organic cosolvent, wherein the occlusive agent is present in an amount sufficient to form an occlusive layer on the skin.</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(5)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7029659B2/US07029659-20060418-D00000.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7029659B2/US07029659-20060418-D00000.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7029659B2/US07029659-20060418-D00001.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7029659B2/US07029659-20060418-D00001.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7029659B2/US07029659-20060418-D00002.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7029659B2/US07029659-20060418-D00002.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7029659B2/US07029659-20060418-D00003.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7029659B2/US07029659-20060418-D00003.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7029659B2/US07029659-20060418-D00004.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7029659B2/US07029659-20060418-D00004.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(39)</span></span></div><div class="patent-text"><div mxw-id="PCLM8997794" lang="EN" load-source="patent-office" class="claims">
    <div class="claim"> <div id="CLM-00001" num="00001" class="claim">
      <div class="claim-text">1. A topical mousse composition, the mousse composition comprising:
<div class="claim-text">(a) an occlusive agent;</div>
<div class="claim-text">(b) an aqueous solvent; and</div>
<div class="claim-text">(c) an organic cosolvent;</div>
<div class="claim-text">wherein the occlusive agent is present in an amount sufficient to form an occlusive layer on the skin.</div>
</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00002" num="00002" class="claim">
      <div class="claim-text">2. The topical mousse composition according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the occlusive agent comprises petrolatum.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00003" num="00003" class="claim">
      <div class="claim-text">3. The topical mousse composition according to <claim-ref idref="CLM-00002">claim 2</claim-ref>, wherein the occlusive agent further comprises a mineral oil and a long chain acid.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00004" num="00004" class="claim">
      <div class="claim-text">4. The topical mousse composition according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the occlusive agent is selected from the group consisting of a mineral oil and grease, a long chain acid, an animal fat and grease, a vegetable fat and grease, and a water insoluble polymer.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00005" num="00005" class="claim">
      <div class="claim-text">5. The topical mousse composition according to <claim-ref idref="CLM-00001">claim 1</claim-ref> or <claim-ref idref="CLM-00002">2</claim-ref>, wherein the occlusive agent is present in an amount of approximately 55% by weight or less, based on the total weight of the composition.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00006" num="00006" class="claim">
      <div class="claim-text">6. The topical mousse composition according to <claim-ref idref="CLM-00005">claim 5</claim-ref>, wherein the occlusive agent is present in an amount of approximately 10 to 50% by weight, based on the total weight of the composition.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00007" num="00007" class="claim">
      <div class="claim-text">7. The topical mousse composition according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, further comprising an effective amount of an emulsifier component.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00008" num="00008" class="claim">
      <div class="claim-text">8. The topical mousse composition according to <claim-ref idref="CLM-00007">claim 7</claim-ref>, wherein the emulsifier component is present in an amount of from approximately 1% to 15% by weight, based on the total weight of the composition.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00009" num="00009" class="claim">
      <div class="claim-text">9. The topical mousse composition according to <claim-ref idref="CLM-00007">claim 7</claim-ref>, wherein the emulsifier component is present in an amount of from approximately 2% to 5% by weight, based on the total weight of the composition.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00010" num="00010" class="claim">
      <div class="claim-text">10. The topical mousse composition according to <claim-ref idref="CLM-00007">claim 7</claim-ref>, wherein the emulsifier component is selected from the group consisting of a non-ionic surfactant, a cationic surfactant, an anionic surfactant, a fatty alcohol, a fatty acid, and fatty acid salts thereof.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00011" num="00011" class="claim">
      <div class="claim-text">11. The topical mousse composition according to <claim-ref idref="CLM-00010">claim 10</claim-ref>, wherein the emulsifier component comprises a mixture of a sorbitan ester and a polyoxyethylene fatty alcohol ether.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00012" num="00012" class="claim">
      <div class="claim-text">12. The topical mousse composition according to <claim-ref idref="CLM-00011">claim 11</claim-ref>, wherein the emulsifier component further comprises a fatty alcohol, a fatty acid or a fatty acid salt.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00013" num="00013" class="claim">
      <div class="claim-text">13. The topical mousse composition according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the aqueous solvent is present in an amount of approximately 25 to 95% by weight, based on the total weight of the composition.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00014" num="00014" class="claim">
      <div class="claim-text">14. The topical mousse composition according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the organic cosolvent is present in an amount of approximately 0.25% by weight to 50% by weight, based on the total weight of the composition.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00015" num="00015" class="claim">
      <div class="claim-text">15. The topical mousse composition according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the organic cosolvent is present in an amount of approximately 0.5% by weight to 2.0% by weight, based on the total weight of the composition.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00016" num="00016" class="claim">
      <div class="claim-text">16. The topical mousse composition according to <claim-ref idref="CLM-00014">claim 14</claim-ref>, wherein the organic cosolvent comprises an alkyl benzoate.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00017" num="00017" class="claim">
      <div class="claim-text">17. The topical mousse composition according to <claim-ref idref="CLM-00014">claim 14</claim-ref>, wherein the organic cosolvent is selected from the group consisting of an alkyl ether, an aromatic ether and a cyclic ether.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00018" num="00018" class="claim">
      <div class="claim-text">18. The topical mousse composition according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, further comprising an effective amount of an aerosol propellant.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00019" num="00019" class="claim">
      <div class="claim-text">19. The topical mousse composition according to <claim-ref idref="CLM-00018">claim 18</claim-ref>, wherein the aerosol propellant is a hydrocarbon and is present in an amount of approximately 2.5 to 20% by weight, based on the total weight of the composition.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00020" num="00020" class="claim">
      <div class="claim-text">20. The topical mousse composition according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, further comprising a water-insoluble pharmaceutically active ingredient.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00021" num="00021" class="claim">
      <div class="claim-text">21. The topical mousse composition according to <claim-ref idref="CLM-00020">claim 20</claim-ref>, wherein said water-insoluble pharmaceutically active ingredient is selected form the group consisting of an analgesic, an antifungal, an antibacterial, an anesthetic, an antiviral, an antipruritic, an antihistamine, a xanthine, a sex hormone, an anti-inflammatory, and a corticosteroid.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00022" num="00022" class="claim">
      <div class="claim-text">22. The topical mousse composition according to <claim-ref idref="CLM-00021">claim 21</claim-ref>, wherein said water-insoluble pharmaceutically active ingredient is an anti-inflammatory.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00023" num="00023" class="claim">
      <div class="claim-text">23. The topical mousse composition according to <claim-ref idref="CLM-00020">claim 20</claim-ref>, wherein the pharmaceutically active ingredient is insoluble in both water and the occlusive agent.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00024" num="00024" class="claim">
      <div class="claim-text">24. The topical mousse composition according to <claim-ref idref="CLM-00020">claim 20</claim-ref>, wherein the pharmaceutically active ingredient is present in an amount of from approximately 0.005% by weight to approximately 10% by weight, based on the total weight of the composition.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00025" num="00025" class="claim">
      <div class="claim-text">25. The topical mousse composition according to <claim-ref idref="CLM-00020">claim 20</claim-ref>, wherein the pharmaceutically active ingredient is present in an amount of from approximately 0.05% by weight to approximately 1% by weight, based on the total weight of the composition.</div>
    </div>
    </div> <div class="claim"> <div id="CLM-00026" num="00026" class="claim">
      <div class="claim-text">26. A topical mousse composition, the mousse composition comprising:
<div class="claim-text">(a) petrolatum in an amount of approximately 10 to 50% by weight, based on the total weight of the composition;</div>
<div class="claim-text">(b) an aqueous solvent; and</div>
<div class="claim-text">(c) an organic cosolvent.</div>
</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00027" num="00027" class="claim">
      <div class="claim-text">27. The topical mousse composition according to <claim-ref idref="CLM-00026">claim 26</claim-ref>, further comprising an effective amount of an emulsifier component.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00028" num="00028" class="claim">
      <div class="claim-text">28. The topical mousse composition according to <claim-ref idref="CLM-00026">claim 26</claim-ref>, further comprising a water-insoluble pharmaceutically active ingredient.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00029" num="00029" class="claim">
      <div class="claim-text">29. The topical mousse composition according to <claim-ref idref="CLM-00026">claim 26</claim-ref>, wherein said water-insoluble pharmaceutically active ingredient is selected form the group consisting of an analgesic, an antifungal, an antibacterial, an anesthetic, an antiviral, an antipruritic, an antihistamine, xanthine, a sex hormone, an anti-inflammatory, and a corticosteroid.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00030" num="00030" class="claim">
      <div class="claim-text">30. The topical mousse composition according to <claim-ref idref="CLM-00029">claim 29</claim-ref>, wherein said water-insoluble pharmaceutically active ingredient is an anti-inflammatory.</div>
    </div>
    </div> <div class="claim"> <div id="CLM-00031" num="00031" class="claim">
      <div class="claim-text">31. A dispenser, the dispenser comprising:
<div class="claim-text">a topical mousse composition comprising:
<div class="claim-text">(a) an occlusive agent;</div>
<div class="claim-text">(b) an aqueous solvent; and</div>
<div class="claim-text">(c) an organic cosolvent;</div>
<div class="claim-text">wherein the occlusive agent is present in an amount sufficient to form an occlusive layer on the skin.</div>
</div>
</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00032" num="00032" class="claim">
      <div class="claim-text">32. The dispenser according to <claim-ref idref="CLM-00031">claim 31</claim-ref>, wherein said occlusive agent in said topical mousse composition comprises petrolatum.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00033" num="00033" class="claim">
      <div class="claim-text">33. The dispenser according to <claim-ref idref="CLM-00031">claim 31</claim-ref>, wherein said topical mousse composition further comprises an effective amount of an emulsifier component.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00034" num="00034" class="claim">
      <div class="claim-text">34. The dispenser according to <claim-ref idref="CLM-00031">claim 31</claim-ref>, wherein said topical mousse composition further comprises a water-insoluble pharmaceutically active ingredient.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00035" num="00035" class="claim">
      <div class="claim-text">35. The dispenser according to <claim-ref idref="CLM-00031">claim 31</claim-ref>, wherein said water-insoluble pharmaceutically active ingredient is selected from the group consisting of an analgesic, an antifungal, an antibacterial, an anesthetic, an antiviral, an antipruritic, an antihistamine, a xanthine, a sex hormone, an anti-inflammatory, and a corticosteroid.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00036" num="00036" class="claim">
      <div class="claim-text">36. The dispenser according to <claim-ref idref="CLM-00035">claim 35</claim-ref>, wherein said water-insoluble pharmaceutically active ingredient is an anti-inflammatory.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00037" num="00037" class="claim">
      <div class="claim-text">37. The topical mousse composition according to <claim-ref idref="CLM-00021">claim 21</claim-ref>, wherein said water-insoluble pharmaceutically active ingredient is a corticosteroid.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00038" num="00038" class="claim">
      <div class="claim-text">38. The topical mousse composition according to <claim-ref idref="CLM-00029">claim 29</claim-ref>, wherein said water-insoluble pharmaceutically active ingredient is a corticosteroid.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00039" num="00039" class="claim">
      <div class="claim-text">39. The dispenser according to <claim-ref idref="CLM-00035">claim 35</claim-ref>, wherein said water-insoluble pharmaceutically active ingredient is a corticosteroid.</div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES16020338" lang="EN" load-source="patent-office" class="description">
    <p num="p-0002">This application is a continuation of U.S. patent application Ser. No. 09/719,662, filed Jan. 30, 2001, now U.S. Pat. No. 6,730,288, which was filed under 35 U.S.C. § 371 as a national stage application of International Application No. PCT/AU99/00735, which claims priority to Australian Patent Application No. PP 5831, the disclosures of each of which are hereby incorporated herein by reference.</p>
    <p num="p-0003">The present invention provides a composition for the topical administration of pharmaceutical active ingredients.</p>
    <p num="p-0004">Various aerosol and non-aerosol quick breaking and slow breaking foams for the topical delivery of pharmaceutical active ingredients are known in the prior art. In particular, the foam composition is an aqueous emulsion system. The foam composition upon actuation produces a stabilised, homogeneous, expandable foam which breaks easily with shear. A composition of this type is often referred to as an aerosol foam or “mousse”.</p>
    <p num="p-0005">It is known to use mousse compositions to topically deliver pharmaceutical active ingredients. An example of such a composition is in Australian patent application 80257/87 which discloses a mousse composition for the topical delivery of the pharmaceutically active ingredient, minoxidil. However the efficiency of such systems to deliver pharmaceutically active ingredients is limited.</p>
    <p num="p-0006">Moreover, the majority of topical lotions and creams known or suggested in the prior art for delivering pharmaceutically active ingredients contain large amounts of petrolatum or some other occlusive agent to act as a barrier over the skin. This barrier reduces the evaporation of moisture from the skin which leads to increased moisture in the stratum corneum and in the epidermis and enhances the topical delivery of the pharmaceutical active ingredients.</p>
    <p num="p-0007">However, in practice it would not be desirable to include such large amounts of an occlusive agent in a mousse formulation because when dispensed the mousse formulation would be a less stable foam, and upon application, the occlusive agent would leave a greasy, sticky lather on the skin which would not be considered acceptable to the consumer.</p>
    <p num="p-0008">In prior art U.S. Pat. Nos. 5,002,680 and 4,981,677, there is disclosed mousse compositions that contain an occlusive agent such as petrolatum. These compositions are directed towards cosmetic purposes, and provide no disclosure on their suitability or otherwise to enhance the topical delivery of pharmaceutical active ingredients. Further, in respect of U.S. Pat. No. 4,981,677 the formulation includes a starch component. It is accordingly not apparent that an occlusive layer would be formed.</p>
    <p num="p-0009">Accordingly, it would be a significant advance in the art if a mousse composition could be provided that enhanced the topical delivery of the pharmaceutical active ingredient while preferably still providing a pharmaceutically elegant and consumer acceptable composition.</p>
    <p num="p-0010">In a first aspect of the present invention there is provided a pharmaceutical aerosol foam composition including an effective amount of
</p> <ul> <li id="ul0001-0001" num="0000"> <ul> <li id="ul0002-0001" num="0010">a pharmaceutically active ingredient</li> <li id="ul0002-0002" num="0011">an occlusive agent</li> <li id="ul0002-0003" num="0012">an aqueous solvent; and</li> <li id="ul0002-0004" num="0013">an organic cosolvent;
<br>
the pharmaceutically active ingredient being insoluble in both water and the occlusive agent;
<br>
the occlusive agent being present in an amount sufficient to form an occlusive layer on the skin, in use.
</li> </ul> </li> </ul> <p num="p-0011">The present invention is predicated on the surprising discovery that a mousse formulation with a relatively low amount of an occlusive agent is still able to reduce trans epidermal water loss and hence in theory increase skin permeability to effect greater drug skin penetration while remaining an elegant and consumer acceptable composition.</p>
    <p num="p-0012">The water-insoluble pharmaceutically active ingredient may be any suitable type. An analgesic such as capsaicin or piroxicam, antifungal such as clotrimazole or miconazole nitrate, antibacterial such as nitrofurazone or gramcidin, anaesthetic such as benzocaine or lidocaine, antiviral such as aciclovir or penciclovir, antipruritic such as crotamiton or phenol, antihistamine such as chlorpheniramine or triprolidine, xanthine such as caffeine, sex hormone such as oestradiol or testosterone, anti-inflammatory agent or corticosteroid may be used. A corticosteroid is preferred. The corticosteroids may be selected from one or more of the group consisting of, betamethasone valerate and clobetasol propionate.</p>
    <p num="p-0013">Clobetasol propionate is preferred.</p>
    <p num="p-0014">The pharmaceutically active ingredient may be present in any effective amounts. The pharmaceutically active ingredient may be present in amounts of approximately 0.005% by weight to approximately 10% by weight, preferably approximately 0.05% to approximately 1% by weight, based on the total weight of the pharmaceutical aerosol foam composition.</p>
    <p num="p-0015">The aerosol foam base can be made using compositions that are well known in the art.</p>
    <p num="p-0016">The pharmaceutical aerosol foam composition may further include an effective amount of an aerosol propellant. The aerosol propellant used in the mousse composition may be any suitable gas, such as a hydrocarbon, e.g. propane, butane, CFCs, HFCs, nitrogen or air. In a preferred embodiment the aerosol propellant is a hydrocarbon. Where the aerosol propellant is a hydrocarbon it may be present in an amount of from approximately 2.5% to 20% by weight, preferably 2.5% to 7.5% by weight, based on the total weight of the pharmaceutical mousse composition. The propellant may be introduced into the mousse composition at the time of filling utilising for example a standard aerosol dispenser, e.g. a spray can arrangement.</p>
    <p num="p-0017">The occlusive agent utilised in the pharmaceutical composition according to the present invention may be any excipient or combination thereof that provides an occlusive layer or hydration barrier to the skin. An occlusive layer or hydration barrier is a layer or barrier sufficient to result in reduction in trans epidermal water loss, which results in skin hydration. Suitable occlusive agents may be selected from one or more of the group consisting of mineral oils and greases, long chain acids, animal fats and greases, vegetable fats and greases, water insoluble polymers and the like. In a preferred embodiment the occlusive agent is petrolatum.</p>
    <p num="p-0018">The occlusive agent is present in an amount sufficient to permit the formation of an occlusive layer or hydration barrier on the skin of the patient. Surprisingly applicants have discovered it is possible to form such an occlusive layer with a relatively low amount of occlusive agent. For example the amount of occlusive agent in the mousse composition may be up to approximately 55%, preferably approximately 40% or less by weight based on the total weight of the composition. In a preferred embodiment of the invention the amount of occlusive agent in the mousse composition may be up to approximately 50%, more preferably from approximately 20 to 50% by weight.</p>
    <p num="p-0019">The pharmaceutical mousse composition may further include an effective amount of an emulsifier and/or surfactant.</p>
    <p num="p-0020">The emulsifier or surfactant may be selected from one or more of the group consisting of non-ionic, anionic and cationic surfactants, e.g. fatty alcohols, fatty acids and fatty acid salts thereof.</p>
    <p num="p-0021">Suitable emulsifiers or surfactants include pharmaceutically acceptable, non-toxic, non-ionic, anionic and cationic surfactants. Examples of suitable non-ionic surfactants include glycerol fatty acid esters such as glycerol monostearate, glycol fatty acid esters such as propylene glycol monostearate, polyhydric alcohol fatty acid esters such as polyethylene glycol (400) monooleate, polyoxyethylene fatty acid esters such as polyoxyethylene (40) stearate, polyoxyethylene fatty alcohol ethers such as polyoxyethylene (20) stearyl ether, polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene sorbitan monostearate, sorbitan esters such as sorbitan monostearate, alkyl glycosides such as cetearyl glucoside, fatty acid ethanolamides and their derivatives such as the diethanolamide of stearic acid, and the like. Examples of suitable anionic surfactants are soaps including alkali soaps, such as sodium, potassium and ammonium salts of aliphatic carboxylic acids, usually fatty acids, such as sodium stearate. Organic amine soaps, also included, include organic amine salts of aliphatic carboxylic acids, usually fatty acids, such as triethanolamine stearate. Another class of suitable soaps is the metallic soaps, salts of polyvalent metals and aliphatic carboxylic acids, usually fatty acids, such as aluminium stearate. Other classes of suitable anionic surfactants include sulfated fatty acid alcohols such as sodium lauryl sulfate, sulfated oils such as the sulfuric ester of ricinoleic acid disodium salt, and sulfonated compounds such as alkyl sulfonates including sodium cetane sulfonate, amide sulfonates such as sodium N-methyl-N-oleyl laurate, sulfonated dibasic acid esters such as sodium dioctyl sulfosuccinate, alkyl aryl sulfonates such as sodium dodecylbenzene sulfonate, alkyl naphthalene sulfonates such a sodium isopropyl naphthalene sulfonate, petroleum sulfonate such as aryl napthalene with alkyl substitutes. Examples of suitable cationic surfactants include amine salts such as octadecyl ammonium chloride, quarternary ammonium compounds such as benzalkonium chloride.</p>
    <p num="p-0022">Surfactants which are a mixture of sorbitan monostearate and polysorbate 60 are preferred.</p>
    <p num="p-0023">The emulsifier component may be present in any suitable stabilising amount. Preferably the emulsifier component may be in an amount where the ratio of emulsifier component to the occlusive agent, active pharmaceutical ingredient and cosolvent is about 1:5. The emulsifier component may be present in an amount of from approximately 1% to 15% by weight, preferably approximately 2.0% to 5.0% by weight, based on the total weight of the pharmaceutical mousse composition.</p>
    <p num="p-0024">The aqueous solvent may be present in an amount of from approximately 25% to 95% by weight, preferably approximately 70% to 85% by weight, based on the total weight of the pharmaceutical mousse composition.</p>
    <p num="p-0025">The composition further includes an organic cosolvent. The organic solvent may be an ester of a fatty acid for example a C12–C15 alkyl benzoate, a medium to long chain alcohol, an aromatic and/or alkyl pyrollidinone, an aromatic and/or alkyl, and/or cyclic ketone, an aromatic and/or alkyl, and/or cyclic ether, substituted and/or unsubstituted single or multiple ring aromatic, straight chain and/or branched chain and/or cyclic alkane or silicone. The organic cosolvent may be present in amounts of approximately 0.25% to 50% by weight, preferably 0.5 to 2% by weight, based on the total weight of the pharmaceutical mousse composition. Preferred organic cosolvents include C12–C15 alkyl benzoates (FINSOLV TN) and caprylic/capric triglyceride (CRODAMOL GTCC).</p>
    <p num="p-0026">The pharmaceutical mousse composition according to the present invention may also contain other non-essential ingredients. The composition may contain up to 10 weight percent of conventional pharmaceutical adjuvants. These adjuvants or additives include preservatives, stabilisers, antioxidants, pH adjusting agents, skin penetration enhancers, and viscosity modifying agents.</p>
    <heading>EXAMPLES</heading> <p num="p-0027">The present invention will now be more fully described with reference to the accompanying figures and examples. It should be understood that the description following is illustrative only and should not be taken in any way as restrictive on the generality of the foregoing description.</p>
    <description-of-drawings> <heading>BRIEF DESCRIPTION OF THE DRAWINGS</heading> <p num="p-0028"> <figref idrefs="DRAWINGS">FIG. 1</figref> illustrates the effect of petrolatum content on in vitro epidermal penetration of clobetasol from topical mousse formulations 72 hours after application of 10 mg/cm<sup>2 </sup>of formulation.</p>
      <p num="p-0029"> <figref idrefs="DRAWINGS">FIG. 2</figref> illustrates the effect of petrolatum content on the rate of transepidermal water loss (TEWL) determined on the forearm of a healthy volunteer 30 and 120 minutes after topical application of 10 mg/cm<sup>2 </sup>of formulation.</p>
      <p num="p-0030"> <figref idrefs="DRAWINGS">FIG. 3</figref> illustrates relative decreases in the rate of transepidermal water loss (TEWL) observed on the forearm of a healthy volunteer with increasing concentrations of petrolatum in topically applied formulations.</p>
      <p num="p-0031"> <figref idrefs="DRAWINGS">FIG. 4</figref> illustrates the effect of application of a 50% petrolatum mousse formulation on the relative rate of TEWL on the forearm of healthy volunteers (mean±SD, n=6).</p>
    </description-of-drawings> <heading>Example 1</heading> <heading>Formulations</heading> <p num="p-0032">A series of 7 pharmaceutical formulations were prepared in accordance with the present invention. The composition of each formulation is given in Table 1.</p>
    <p num="p-0033">
      <tables id="TABLE-US-00001" num="00001"> <table frame="none" colsep="0" rowsep="0" pgwide="1" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="8"> <colspec colname="1" colwidth="70pt" align="left"> </colspec> <colspec colname="2" colwidth="28pt" align="center"> </colspec> <colspec colname="3" colwidth="28pt" align="center"> </colspec> <colspec colname="4" colwidth="28pt" align="center"> </colspec> <colspec colname="5" colwidth="28pt" align="center"> </colspec> <colspec colname="6" colwidth="28pt" align="center"> </colspec> <colspec colname="7" colwidth="28pt" align="center"> </colspec> <colspec colname="8" colwidth="28pt" align="center"> </colspec> <thead> <tr class="description-tr"> <td namest="1" nameend="8" rowsep="1" class="description-td" colspan="8">TABLE 1</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="8" align="center" rowsep="1" class="description-td" colspan="8"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ingredient</td>
                <td class="description-td">1</td>
                <td class="description-td">2</td>
                <td class="description-td">3</td>
                <td class="description-td">4</td>
                <td class="description-td">5</td>
                <td class="description-td">6</td>
                <td class="description-td">7</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="8" align="center" rowsep="1" class="description-td" colspan="8"> </td>
              </tr> </thead> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Petrolatum</td>
                <td class="description-td">  10%</td>
                <td class="description-td">  10%</td>
                <td class="description-td">  20%</td>
                <td class="description-td">  30%</td>
                <td class="description-td">  30%</td>
                <td class="description-td">  40%</td>
                <td class="description-td">  50%</td>
              </tr> <tr class="description-tr"> <td class="description-td">Clobetasol Propionate</td>
                <td class="description-td"> 0.05%</td>
                <td class="description-td"> 0.05%</td>
                <td class="description-td"> 0.05%</td>
                <td class="description-td"> 0.05%</td>
                <td class="description-td"> 0.05%</td>
                <td class="description-td"> 0.05%</td>
                <td class="description-td"> 0.05%</td>
              </tr> <tr class="description-tr"> <td class="description-td">Caprylic/Capric</td>
                <td class="description-td">—</td>
                <td class="description-td">—</td>
                <td class="description-td">—</td>
                <td class="description-td">—</td>
                <td class="description-td">  10%</td>
                <td class="description-td">—</td>
                <td class="description-td">—</td>
              </tr> <tr class="description-tr"> <td class="description-td">Triglyceride</td>
              </tr> <tr class="description-tr"> <td class="description-td">Alkyl Benzoate</td>
                <td class="description-td">  10%</td>
                <td class="description-td">  10%</td>
                <td class="description-td">  10%</td>
                <td class="description-td">  10%</td>
                <td class="description-td">—</td>
                <td class="description-td">  10%</td>
                <td class="description-td">  10%</td>
              </tr> <tr class="description-tr"> <td class="description-td">Cetearyl glucoside</td>
                <td class="description-td"> 2.5%</td>
                <td class="description-td">—</td>
                <td class="description-td">—</td>
                <td class="description-td">—</td>
                <td class="description-td">—</td>
                <td class="description-td">—</td>
                <td class="description-td">—</td>
              </tr> <tr class="description-tr"> <td class="description-td">Sorbitan Stearate</td>
                <td class="description-td">—</td>
                <td class="description-td"> 1.63%</td>
                <td class="description-td"> 2.54%</td>
                <td class="description-td"> 3.44%</td>
                <td class="description-td"> 3.02%</td>
                <td class="description-td"> 4.35%</td>
                <td class="description-td"> 5.25%</td>
              </tr> <tr class="description-tr"> <td class="description-td">Polysorbate 60</td>
                <td class="description-td">—</td>
                <td class="description-td"> 2.37%</td>
                <td class="description-td"> 3.46%</td>
                <td class="description-td"> 4.56%</td>
                <td class="description-td"> 4.98%</td>
                <td class="description-td"> 5.65%</td>
                <td class="description-td"> 6.75%</td>
              </tr> <tr class="description-tr"> <td class="description-td">Water</td>
                <td class="description-td">72.25%</td>
                <td class="description-td">70.95%</td>
                <td class="description-td">58.95%</td>
                <td class="description-td">46.95%</td>
                <td class="description-td">46.95%</td>
                <td class="description-td">34.95%</td>
                <td class="description-td">22.95%</td>
              </tr> <tr class="description-tr"> <td class="description-td">Preservatives</td>
                <td class="description-td"> 0.2%</td>
                <td class="description-td">—</td>
                <td class="description-td">—</td>
                <td class="description-td">—</td>
                <td class="description-td">—</td>
                <td class="description-td">—</td>
                <td class="description-td">—</td>
              </tr> <tr class="description-tr"> <td class="description-td">Propellant</td>
                <td class="description-td">   5%</td>
                <td class="description-td">   5%</td>
                <td class="description-td">   5%</td>
                <td class="description-td">   5%</td>
                <td class="description-td">   5%</td>
                <td class="description-td">   5%</td>
                <td class="description-td">   5%</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="8" align="center" rowsep="1" class="description-td" colspan="8"> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <heading>Example 2</heading> <heading>Effect of Petrolatum Concentration on the In-vitro Epidermal Penetration of Clobetasol from Topical Mousse Formulations</heading> <p num="h-0007">Aim</p>
    <p num="p-0034">The aim of the study was to:
</p> <ul> <li id="ul0003-0001" num="0000"> <ul> <li id="ul0004-0001" num="0038">(1) determine the penetration of the steroid clobetasol into human epidermis following topical application of mousse formulations to which increasing concentrations of petrolatum had been included as a potential occlusive agent and penetration enhancer.</li> <li id="ul0004-0002" num="0039">(2) To assess clobetasol penetration following application to intact epidermis and that which had been stripped 3 times with tape to model the impaired stratum corneum barrier function seen in the dermatological conditions for which the drug is used clinically.
<br>
Method
</li> </ul> </li> </ul> <p num="p-0035">Preparation of epidermal membranes: Donated human female abdominal skin was separated by blunt dissection, to remove subcutaneous fat and extraneous tissue, and immersed in water at 60° C. for 2 minutes to allow separation of the epidermal-dermal junction. Epidermal membranes were lifted from the dermis by gently rolling from one end with the fingers and stored on filter paper, stratum corneum uppermost, at −20° C. until use.</p>
    <p num="p-0036">Diffusion Studies Epidermal membranes were mounted, stratum corneum uppermost and facing the donor chamber, on filter paper between the two halves of standard horizontal glass Franz-type diffusion cells (area approx. 1.3 cm<sup>2</sup>). The bottom half of the diffusion cells was filled with approximately 3.5 ml of receptor medium (either 20% ethanol in distilled water for intact epidermal membrane studies or Baxter 20% Intralipid® solution for stripped skin studies) and continuously stirred with small magnetic fleas. Assembled cells were semi-submerged in a water bath maintained at 35±0.1° C.</p>
    <p num="p-0037">Mousse formulations containing 0.05% clobetasol with the inclusion of 0, 30 or 50% petrolatum were gently applied to the donor chamber with a round-ended plastic rod which was wiped around the skin surface such that the skin was covered by a total dose of approximately 10 mg/cm<sup>2</sup>. The weight of formulation applied was verified from the difference in weight of the application rod and small weigh boat from which the formulation had been applied before and after dosing.</p>
    <p num="p-0038">Clobetasol was allowed to penetrate into the epidermis for 72 hrs after which time the remaining formulation was removed from the skin surface by washing and a single tape strip was performed to ensure that minimal ‘unpenetrated’ material remained on the surface of the epidermis. All washes and tape strips were retained for quantification of clobetasol concentration. The area of epidermis exposed to the formulation was then removed from the membrane using a stainless steel punch which was cleaned with methanol between samples to avoid any cross contamination of clobetasol. Epidermal, tape and wash samples were all assayed for clobetasol concentration by high performance liquid chromatography.</p>
    <p num="h-0008">Results</p>
    <p num="p-0039"> <figref idrefs="DRAWINGS">FIG. 1</figref> shows the fraction of the applied amount of clobetasol that was found to have penetrated into the epidermal membranes during the study. It can be clearly seen that inclusion of petrolatum in the mousse formulations has increased the amount of clobetasol penetrating into the epidermis of both intact and stripped skin samples. The recovery of the applied amounts of clobetasol in the washes, tape strip and epidermis was greater than 75% in all cases.</p>
    <p num="h-0009">Conclusion</p>
    <p num="p-0040">Increasing concentrations of petrolatum in topical mousse formulations containing 0.05% clobetasol was able to increase the in-vitro human epidermal penetration of the steroid in both intact and stripped skin models.</p>
    <heading>Example 3a</heading> <heading>The Effect of Petrolatum Concentration on the Occlusivity of Topical Mousse Formulations</heading> <p num="h-0012">Aim</p>
    <p num="p-0041">The aim of the study was to determine whether increasing the concentration of petrolatum in topical mousse formulations could effectively occlude the underlying skin and thereby lead to increased local hydration which in turn is known to improve the percutaneous penetration of suitable drugs.</p>
    <p num="h-0013">Method</p>
    <p num="p-0042">Relative degrees of occlusion of the skin in humans can be effectively quantified by following changes in the normal rate of transepidermal water loss (TEWL) caused by procedures such as formulation application. In the present study a commercially available single probe TEWL meter (Tewameter, Courage and Khazaka, Cologne, Germany) was used to determine the rate of TEWL (g/hr/m<sup>2</sup>) at a number of 2×2 cm numbered test squares marked on the medial side of the forearm of a healthy volunteer. Baseline readings of TEWL were taken in triplicate at each test site prior to the application of mousse formulation at a dose of 10 mg/cm<sup>2 </sup>containing 0, 10, 20, 30, 40 or 50% petrolatum. To ensure that the dose rate of 10 mg/cm<sup>2 </sup>was maintained for each formulation, approximately 40 mg of each mousse was weighed out onto a 2 cm wide glass slide which was then used to wipe the mousse evenly across each one of the marked test squares before being reweighed to determine the total amount of mousse transferred onto the skin.</p>
    <p num="p-0043">At 30 and 120 minutes following mousse application determinations of TEWL were repeated at each of the test sites. Relative changes in TEWL were then calculated by dividing the rate of TEWL following application by that taken from the same marked square at t=0.</p>
    <p num="h-0014">Results</p>
    <p num="p-0044"> <figref idrefs="DRAWINGS">FIG. 2</figref> shows the actual rate of TEWL (g/hr/m<sup>2</sup>) determined at each of the test sites prior to treatment and again at 30 and 120 minutes after mousse application. A decrease in the rate of TEWL was observed with increasing concentrations of petrolatum in the mousse formulations at both 30 and 120 minutes following application. <figref idrefs="DRAWINGS">FIG. 2</figref> clearly shows the relationship between the % of petrolatum content in each of the test mousses and the resultant relative change in the rate of TEWL determined at 30 and 120 minutes after formulation application.</p>
    <p num="h-0015">Conclusion</p>
    <p num="p-0045">Increasing the concentration of petrolatum in topical mousse formulations was able to decrease the normal rate of TEWL on the forearm of a healthy volunteer. The decreases in the rate TEWL observed effectively demonstrate that increasing the concentration of petrolatum in the product leads to an increase in the relative occlusivity of the topical mousse formulations tested</p>
    <heading>Example 3b</heading> <p num="h-0017">Part 2</p>
    <p num="h-0018">Aim</p>
    <p num="p-0046">The aim of the second part of this study was to assess the degree of occlusivity afforded by the 50% petrolatum mousse formulation in a number of healthy volunteers.</p>
    <p num="h-0019">Method</p>
    <p num="p-0047">The effect of a 10 mg/cm<sup>2 </sup>dose of 50% mousse formulation on the normal rate of TEWL was determined on the forearm of 6 volunteers in a manner identical to that described above. The relative changes observed in the rate of TEWL at 30 and 120 min after application were then compared to an untreated control site measured at the same time on the tested forearm of each volunteer.</p>
    <p num="h-0020">Results</p>
    <p num="p-0048"> <figref idrefs="DRAWINGS">FIG. 4</figref> shows the relative rates of TEWL determined at the 2 test sites on the forearms of the volunteers. Significant decreases in TEWL (P&lt;0.05, ANOVA and Students t-test) were observed at both the 30 and 120 min post-treatment tests following application of the 50% petrolatum mousse formulation. No significant difference was observed in the rate of TEWL between the control sites over the 120 min test period (P=0.19, ANOVA).</p>
    <p num="h-0021">Conclusion</p>
    <p num="p-0049">Application of a mousse formulation containing 50% petrolatum at a dose of 10 mg/cm<sup>2 </sup>significantly occluded the skin as determined by decreases in the rate of TEWL observed on the forearms of 6 healthy volunteers.</p>
    <p num="p-0050">Finally, it is to be understood that various alterations, modifications and/or additions may be made without departing from the spirit of the present invention as outlined herein.</p>
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5143717">US5143717</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 2, 1989</td><td class="patent-data-table-td patent-date-value">Sep 1, 1992</td><td class="patent-data-table-td ">Code Blue Medical Corporation</td><td class="patent-data-table-td ">Burn foam and delivery system</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5733558">US5733558</a></td><td class="patent-data-table-td patent-date-value">Apr 22, 1996</td><td class="patent-data-table-td patent-date-value">Mar 31, 1998</td><td class="patent-data-table-td ">L&#39;oreal</td><td class="patent-data-table-td ">Method for treatment of acne and/or the effects of ageing using HMG-coenzyme A-reductase inhibitor and compositions for performing the same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5833960">US5833960</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 29, 1997</td><td class="patent-data-table-td patent-date-value">Nov 10, 1998</td><td class="patent-data-table-td ">Beiersdorf Ag</td><td class="patent-data-table-td ">Foaming light protection preparations containing water-soluble light protection filters and surface-active substances</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6730288">US6730288</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 8, 1999</td><td class="patent-data-table-td patent-date-value">May 4, 2004</td><td class="patent-data-table-td ">Connetics Australia Pty Ltd</td><td class="patent-data-table-td ">Lower level of occlusive agent; greater drug skin penetration</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0484530A1?cl=en">EP0484530A1</a></td><td class="patent-data-table-td patent-date-value">Jul 23, 1990</td><td class="patent-data-table-td patent-date-value">May 13, 1992</td><td class="patent-data-table-td ">Hisamitsu Pharmaceutical Co. Inc.</td><td class="patent-data-table-td ">Foamed aerosol preparation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="http://www.google.com/url?id=7qByBAABERAJ&amp;q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DGB%26NR%3D2327344A%26KC%3DA%26FT%3DD&amp;usg=AFQjCNH2q52dEp1_0y_YrCwYoWjO8IPGwQ">GB2327344A</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td "> </td><td class="patent-data-table-td citation-no-title">Title not available</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1993025189A1?cl=en">WO1993025189A1</a></td><td class="patent-data-table-td patent-date-value">Jun 18, 1992</td><td class="patent-data-table-td patent-date-value">Dec 23, 1993</td><td class="patent-data-table-td ">Ballard Med Prod</td><td class="patent-data-table-td ">Burn foam and delivery system</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1996027376A1?cl=en">WO1996027376A1</a></td><td class="patent-data-table-td patent-date-value">Mar 1, 1996</td><td class="patent-data-table-td patent-date-value">Sep 12, 1996</td><td class="patent-data-table-td ">Medeva Plc</td><td class="patent-data-table-td ">Corticosteroid-containing pharmaceutical composition</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1999004751A2?cl=en">WO1999004751A2</a></td><td class="patent-data-table-td patent-date-value">Jul 10, 1998</td><td class="patent-data-table-td patent-date-value">Feb 4, 1999</td><td class="patent-data-table-td ">Unilever Nv</td><td class="patent-data-table-td ">Stable liquid composition comprising high levels of emollients</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2000015193A1?cl=en">WO2000015193A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 8, 1999</td><td class="patent-data-table-td patent-date-value">Mar 23, 2000</td><td class="patent-data-table-td ">Soltec Res Pty Ltd</td><td class="patent-data-table-td ">Mousse composition</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Zorko, et al., "<a href='http://scholar.google.com/scholar?q="Mousses"'>Mousses</a>"; Handbook of Cosmetic Science and Technology; pp. 221-232; Marcel Dekker, Inc.; New York (2000).</td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7316810">US7316810</a></td><td class="patent-data-table-td patent-date-value">Nov 13, 2000</td><td class="patent-data-table-td patent-date-value">Jan 8, 2008</td><td class="patent-data-table-td ">Galderma S.A.</td><td class="patent-data-table-td ">Foaming composition for washing and treating hair and/or scalp based on an active principle</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7700081">US7700081</a></td><td class="patent-data-table-td patent-date-value">Jun 16, 2006</td><td class="patent-data-table-td patent-date-value">Apr 20, 2010</td><td class="patent-data-table-td ">Galderma S.A.</td><td class="patent-data-table-td ">Psoriasis; applying daily to hair an aqueous mixture of clobetasol propionate, an anionic surfactant, an amphoteric surfactant, and ethanol; leaving it for 2.5 to 15 minutes, and rinsing with water.</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8066975">US8066975</a></td><td class="patent-data-table-td patent-date-value">Nov 13, 2007</td><td class="patent-data-table-td patent-date-value">Nov 29, 2011</td><td class="patent-data-table-td ">Galderma S.A.</td><td class="patent-data-table-td ">Psoriasis or seborrheic dermatitis; mixture of clobetasol propionate, an anionic surfactant (sodium lauryl ether sulfate), an amphoteric surfactant ( cocamidopropyl betaines); a propenetrating agent chosen from ethanol, isopropanol, propylene glycol and ethoxydiglycol; foam with good compactnes; shampoo</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8066976">US8066976</a></td><td class="patent-data-table-td patent-date-value">Mar 16, 2010</td><td class="patent-data-table-td patent-date-value">Nov 29, 2011</td><td class="patent-data-table-td ">Galderma S.A.</td><td class="patent-data-table-td ">Foaming compositions for hair care</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8263580">US8263580</a></td><td class="patent-data-table-td patent-date-value">May 26, 2006</td><td class="patent-data-table-td patent-date-value">Sep 11, 2012</td><td class="patent-data-table-td ">Stiefel Research Australia Pty Ltd</td><td class="patent-data-table-td ">Vitamin formulation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8298515">US8298515</a></td><td class="patent-data-table-td patent-date-value">Sep 28, 2010</td><td class="patent-data-table-td patent-date-value">Oct 30, 2012</td><td class="patent-data-table-td ">Stiefel Research Australia Pty Ltd.</td><td class="patent-data-table-td ">Vitamin formulation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8629128">US8629128</a></td><td class="patent-data-table-td patent-date-value">Sep 20, 2012</td><td class="patent-data-table-td patent-date-value">Jan 14, 2014</td><td class="patent-data-table-td ">Stiefel West Coast, Llc</td><td class="patent-data-table-td ">Vitamin formulation</td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc424/defs424.htm&usg=AFQjCNH9_TEmt6LWxUKihruum311Bzz0Rg#C424S045000">424/45</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S945000">514/945</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc424/defs424.htm&usg=AFQjCNH9_TEmt6LWxUKihruum311Bzz0Rg#C424S401000">424/401</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc424/defs424.htm&usg=AFQjCNH9_TEmt6LWxUKihruum311Bzz0Rg#C424S059000">424/59</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S730000">514/730</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S861000">514/861</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S859000">514/859</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc424/defs424.htm&usg=AFQjCNH9_TEmt6LWxUKihruum311Bzz0Rg#C424S078030">424/78.03</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S947000">514/947</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S887000">514/887</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S846000">514/846</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0009000000">A61K9/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0009120000">A61K9/12</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A01N0025040000">A01N25/04</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A01N0025060000">A01N25/06</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0009100000">A61K9/10</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031573000">A61K31/573</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0005380000">A61P5/38</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0047120000">A61K47/12</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0047140000">A61K47/14</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0008040000">A61K8/04</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0047100000">A61K47/10</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0047440000">A61K47/44</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0047460000">A61K47/46</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0047060000">A61K47/06</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=Y10S514/859">Y10S514/859</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=Y10S514/861">Y10S514/861</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=Y10S514/887">Y10S514/887</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=Y10S514/945">Y10S514/945</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=Y10S514/846">Y10S514/846</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=Y10S514/947">Y10S514/947</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K9/0014">A61K9/0014</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7qByBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K9/122">A61K9/122</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">A61K9/12B</span>, <span class="nested-value">A61K9/00M3</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">Oct 4, 2013</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">8</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">May 30, 2013</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:STIEFEL RESEARCH AUSTRALIA PTY LTD;REEL/FRAME:030511/0963</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">STIEFEL WEST COAST, LLC, DELAWARE</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20130530</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Feb 22, 2010</td><td class="patent-data-table-td ">SULP</td><td class="patent-data-table-td ">Surcharge for late payment</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Sep 16, 2009</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jun 23, 2009</td><td class="patent-data-table-td ">B1</td><td class="patent-data-table-td ">Reexamination certificate first reexamination</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CLAIMS 2, 7, 18, 20, 23, 28 AND 34 ARE CANCELLED. CLAIMS 1, 3-6, 8-10, 13-15, 17, 19, 21, 22, 24-27, 29-33 AND 35-39 ARE DETERMINED TO BE PATENTABLE AS AMENDED. NEW CLAIMS 40-79 ARE ADDED AND DETERMINED TO BE PATENTABLE. CLAIMS 11, 12 AND 16 WERE NOT REEXAMINED.</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jun 2, 2009</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">STIEFEL RESEARCH AUSTRALIA PTY LTD, AUSTRALIA</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF NAME;ASSIGNOR:CONNETICS AUSTRALIA PTY. LTD.;REEL/FRAME:022773/0140</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20070326</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Feb 13, 2007</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20061128</span></div></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_8a2b04e7bf975d5171d8e4c0b6365c7a.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U0Z6EWHVsysHixm9epunqLX99F45w\u0026id=7qByBAABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U0k6o2-oDR5SRktCf7Y4wIu9Dc5yA\u0026id=7qByBAABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U3T_H1P2AeNwrry3p-UrecWhS6yWA","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/aqueous_solvent_organic_cosolvent_and_oc.pdf?id=7qByBAABERAJ\u0026output=pdf\u0026sig=ACfU3U0Pp0rygNP6sDJXTEQ1isC77BhgDQ"},"sample_url":"http://www.google.com/patents/reader?id=7qByBAABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>